Tetsuya Mitsudomi

List of Publications by Year
in descending order

334	42,323	4658 85	2385 198
papers	citations	h-index	g-index

339	339	339	30507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 289-301.e2.	0.8	159
2	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Nonâ€“Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology, 2022, 40, 231-241.	1.6	61
3	Utility of the Ba/F3 cell system for exploring onâ€target mechanisms of resistance to targeted therapies for lung cancer. Cancer Science, 2022, 113, 815-827.	3.9	11
4	Presence of a Ground-glass Opacity Component is the True Prognostic Determinant in Clinical Stage I Non-Small Cell Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100321.	1.1	1
5	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	27.0	871
6	Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2022, 399, 1607-1617.	13.7	537
7	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 2022, 170, 41-51.	2.0	33
8	Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). International Journal of Clinical Oncology, 2022, 27, 1404-1412.	2.2	1
9	Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of Hematology and Oncology, 2022, 15, .	17.0	19
10	Lung Cancer and <i>KRAS</i> -Its Molecular Biology/Genetics and Therapeutic Strategy-. Japanese Journal of Lung Cancer, 2022, 62, 188-199.	0.1	0
11	Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Annals of Thoracic Surgery, 2021, 111, 269-276.	1.3	66
12	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Nonâ€“Small Cell Lung Cancers: Analysis of Five Cases. Clinical Lung Cancer, 2021, 22, e141-e145.	2.6	5
13	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq1 1 0.784314 rgBT /Overlock	4.3	5
14	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancersâ€”Applications and Limitations. Cells, 2021, 10, 354.	4.1	9
15	Integrinâ€linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. Oncology Letters, 2021, 21, 320.	1.8	2
16	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 153, 108-116.	2.0	28
17	Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor. JTO Clinical and Research Reports, 2021, 2, 100134.	1.1	3
18	Activity of <scp>tarloxotinibâ€E</scp> in cells with <scp>EGFR</scp> exonâ€20 insertion mutations and mechanisms of acquired resistance. Thoracic Cancer, 2021, 12, 1511-1516.	1.9	15

#	Article	IF	Citations
19	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Nonâ€“small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer, 2021, 22, 596-600.	2.6	14
20	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer, 2021, 154, 84-91.	2.0	9
21	Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer: Targets and Therapy, 2021, Volume 12, 35-50.	2.7	25
22	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From InÂVitro Experiments. Journal of Thoracic Oncology, 2021, 16, 1321-1332.	1.1	118
23	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations. Cells, 2021, 10, 1590.	4.1	16
24	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 4035.	3.7	18
25	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational Lung Cancer Research, 2021, 10, 3659-3670.	2.8	7
26	Intra-tumor and inter-tumor heterogeneity in MET exon 14 skipping mutations and co-mutations in pulmonary pleomorphic carcinomas. Clinical Lung Cancer, 2021, , .	2.6	0
27	Adjuvant therapy of operable nonsmall cell lung cancer: an update. Current Opinion in Oncology, 2021, 33, 47-54.	2.4	13
28	Frequent EGFR mutations and better prognosis in positron emission tomography-negative, solid-type lung cancer. Clinical Lung Cancer, 2021, , .	2.6	3
29	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. Lung Cancer, 2021, 162, 79-85.	2.0	1
30	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	2.9	15
31	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	2.0	100
32	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer, 2020, 148, 100-104.	2.0	6
33	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2187-2196.	1.6	78
34	Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?. Journal of Thoracic Disease, 2020, 12, 1770-1775.	1.4	11
35	Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2020, 25, 229-249.	2.4	27
36	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205

#	Article	IF	Citations
37	Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. Translational Lung Cancer Research, 2020, 9, 2618-2628.	2.8	23
38	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	3.0	4
39	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	3.9	22
40	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors InÂVitro. Journal of Thoracic Oncology, 2019, 14, 1753-1765.	1.1	105
41	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. Surgical Case Reports, 2019, 5, 105.	0.6	1
42	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. Biomolecules, 2019, 9, 456.	4.0	11
43	Brain metastases in oncogene-driven non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S298-S307.	2.8	41
44	Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. Surgery Today, 2019, 49, 513-520.	1.5	3
45	BRAF Fusion â€" Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2019, 14, 764-765.	1.1	3
46	Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 895-907.	0.8	347
47	Ground glass nodules with 5 yearsâ€™ stability can grow after 10-year follow-up: do genetic features determine the fate?. Translational Lung Cancer Research, 2019, 8, S425-S427.	2.8	1
48	Osimertinib in patients with T790M mutationâ€positive, advanced nonâ€“small cell lung cancer: Longâ€term followâ€up from a pooled analysis of 2 phase 2 studies. Cancer, 2019, 125, 892-901.	4.1	117
49	EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. Journal of Thoracic Oncology, 2018, 13, 727-731.	1.1	39
50	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.	2.2	14
51	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2018, 121, 37-40.	2.0	62
52	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 792-800.	1.1	17
53	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFRâ€mutant Ba/F3 cells. Oncology Reports, 2018, 41, 1059-1066.	2.6	6
54	Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Translational Lung Cancer Research, 2018, 7, 487-497.	2.8	45

#	Article	IF	Citations
55	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer, 2018, 126, 149-155.	2.0	40
56	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer, 2018, 126, 72-79.	2.0	59
57	Innate Genetic Evolution of Lung Cancers andÂSpatial Heterogeneity: Analysis of Treatment-NaÃ¯ve Lesions. Journal of Thoracic Oncology, 2018, 13, 1496-1507.	1.1	22
58	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 2257-2265.	4.1	41
59	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer, 2017, 104, 85-90.	2.0	39
60	Heterogeneity in Immune Marker Expression afterÂAcquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell LungÂCancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	1.1	20
61	Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation. Lancet Respiratory Medicine,the, 2017, 5, 369-370.	10.7	0
62	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27
63	Plasma ctDNA Analysis for Detection of the EGFR ÂT790M Mutation in Patients with Advanced Nonâ€“SmallÂCell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1061-1070.	1.1	240
64	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	13.7	753
65	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 357-364.	4.1	65
66	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer, 2017, 17, 281.	2.6	31
67	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	2.6	13
68	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 109, .	6.3	196
69	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer, 2017, 112, 57-61.	2.0	16
70	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Review of Anticancer Therapy, 2017, 17, 779-786.	2.4	27
71	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: ProposalÂfrom the Bench. Journal of Thoracic Oncology, 2017, 12, 27-35.	1.1	24
72	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	1.9	13

#	Article	IF	Citations
73	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE, 2017, 12, e0172209.	2.5	13
74	The History and Current State of EGFR-TKIs. Japanese Journal of Lung Cancer, 2017, 57, 69-74.	0.1	1
75	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. Translational Lung Cancer Research, 2016, 5, 446-449.	2.8	6
76	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. PLoS ONE, 2016, 11, e0154186.	2.5	15
77	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711ÂL (PEOPLE Study). Respiratory Research, 2016, 17, 90.	3.6	93
78	Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	2.9	50
79	<scp>FGFR</scp> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676.	3.9	31
80	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€"Positive Nonâ€"Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	1.1	173
81	Heterogeneity in Tumors and Resistance to EGFR TKI Therapyâ€"Letter. Cancer Research, 2016, 76, 3109-3110.	0.9	6
82	The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study. Lung Cancer, 2016, 97, 1-7.	2.0	25
83	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 822-835.	10.7	390
84	Sensitivities to various epidermal growth factor receptorâ€tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptorâ€tyrosine kinase inhibitor?. Cancer Science, 2016, 107, 1134-1140.	3.9	78
85	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology, 2016, 11, 1711-1717.	1.1	12
86	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptorâ€tyrosine kinase inhibitor in lung cancer. Cancer Science, 2016, 107, 461-468.	3.9	31
87	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Science, 2016, 107, 1179-1186.	3.9	305
88	MEK inhibitors against MET-amplified non-small cell lung cancer. International Journal of Oncology, 2016, 49, 2236-2244.	3.3	24
89	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2016, 17, 1643-1652.	10.7	533
90	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 895-901.	1.1	30

#	Article	IF	Citations
91	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO Open, 2016, 1, e000063.	4.5	37
92	Prognostic impact of pleural lavage cytology in patients with primary lung cancer. Lung Cancer, 2016, 102, 60-64.	2.0	8
93	Clinical outcome of nodeâ€negative oligometastatic nonâ€“small cell lung cancer. Thoracic Cancer, 2016, 7, 670-675.	1.9	6
94	Impact of bevacizumab in combination with erlotinib on <scp>EGFR</scp>â€mutated nonâ€“small cell lung cancer xenograft models with <scp>T790M</scp> mutation or <scp>MET</scp> amplification. International Journal of Cancer, 2016, 138, 1024-1032.	5.1	35
95	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer, 2016, 98, 69-75.	2.0	136
96	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	2.9	50
97	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer, 2016, 91, 36-40.	2.0	38
98	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Nonâ€“Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research, 2016, 22, 3663-3671.	7.0	14
99	Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection. Thoracic Cancer, 2015, 6, 655-658.	1.9	4
100	Prognosis and segmentâ€specific nodal spread of primary lung cancer in the right lower lobe. Thoracic Cancer, 2015, 6, 672-677.	1.9	10
101	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Scientific Reports, 2015, 5, 14447.	3.3	71
102	<scp>G</scp>enetic variants associated with longer telomere length are associated with increased lung cancer risk among neverâ€smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	5.1	72
103	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
104	Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib. PLoS ONE, 2015, 10, e0123901.	2.5	12
105	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Archives of Toxicology, 2015, 89, 1227-1240.	4.2	42
106	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research, 2015, 21, 5305-5313.	7.0	164
107	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	1.6	280
108	Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations. Journal of Thoracic Oncology, 2015, 10, 59-66.	1.1	13

#	Article	IF	Citations
109	Racial Differences in Lung Cancer Genetics. Journal of Thoracic Oncology, 2015, 10, 230-231.	1.1	6
110	Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage IIâ€“IIIA Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 5245-5252.	7.0	25
111	Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema. Annals of Surgical Oncology, 2015, 22, 1371-1379.	1.5	44
112	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer, 2015, 90, 590-597.	2.0	32
113	Successes and Limitations of Targeted Cancer Therapy in Lung Cancer. Progress in Tumor Research, 2014, 41, 62-77.	0.1	34
114	Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma. BioMed Research International, 2014, 2014, 1-6.	1.9	9
115	Dacomitinib: another option for EGFR-mutant lung cancer?. Lancet Oncology, The, 2014, 15, 1408-1409.	10.7	6
116	Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respiratory Investigation, 2014, 52, 322-329.	1.8	16
117	Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2014, 45, 687-692.	1.4	12
118	Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1604-1611.e3.	0.8	245
119	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. Lung Cancer, 2014, 83, 23-29.	2.0	12
120	Risk assessment of perioperative mortality after pulmonary resection in patients with primary lung cancer: the 30- or 90-day mortality. General Thoracic and Cardiovascular Surgery, 2014, 62, 308-313.	0.9	10
121	The insulinâ€like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wildâ€type epidermal growth factor receptor. International Journal of Cancer, 2014, 135, 1002-1006.	5.1	49
122	The association between baseline clinicalâ€“radiological characteristics and growth of pulmonary nodules with ground-glass opacity. Lung Cancer, 2014, 83, 61-66.	2.0	87
123	CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Lung Cancer, 2014, 85, 147-151.	2.0	13
124	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Journal of Clinical Investigation, 2014, 124, 3003-3015.	8.2	84
125	Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Translational Lung Cancer Research, 2014, 3, 205-11.	2.8	64
126	Paravertebral block via the surgical field versus epidural block for patients undergoing thoracotomy: a randomized clinical trial. Surgery Today, 2013, 43, 963-969.	1.5	32

#	Article	IF	Citations
127	Outcomes After Hepatic and Pulmonary Metastasectomies Compared With Pulmonary Metastasectomy Alone in Patients With Colorectal Cancer Metastasis to Liver and Lungs. World Journal of Surgery, 2013, 37, 1315-1321.	1.6	31
128	Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. Surgery Today, 2013, 43, 1382-1389.	1.5	20
129	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 2013, 81, 97-101.	2.0	42
130	Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 24-30.	0.8	279
131	Solitary pulmonary metastasis from lung cancer harboring EML4â€“ALK after a 15-year disease-free interval. Lung Cancer, 2013, 80, 99-101.	2.0	8
132	Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer, 2013, 80, 249-255.	2.0	60
133	Surgery for NSCLC in the era of personalized medicine. Nature Reviews Clinical Oncology, 2013, 10, 235-244.	27.6	85
134	Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies. Journal of Thoracic Oncology, 2013, 8, e75-e78.	1.1	37
135	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405). Japanese Journal of Clinical Oncology, 2013, 43, 664-668.	1.3	38
136	Unintentional Weakness of Cancers: The MEKâ€“ERK Pathway as a Double-Edged Sword. Molecular Cancer Research, 2013, 11, 1125-1128.	3.4	2
137	How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?. Journal of Thoracic Oncology, 2013, 8, 309-314.	1.1	91
138	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	1.1	113
139	HNF4Î± as a Marker for Invasive Mucinous Adenocarcinoma of the Lung. American Journal of Surgical Pathology, 2013, 37, 211-218.	3.7	74
140	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets and Therapy, 2013, 4, 43.	2.7	3
141	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro.. Cancer Research, 2013, 73, 2101A-2101A.	0.9	6
142	Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?. Translational Lung Cancer Research, 2013, 2, 354-63.	2.8	84
143	Risk Assessment of Perioperative Mortality After Pulmonary Resection for Primary Lung Cancer: the 30-day or 90-day Mortality. Japanese Journal of Lung Cancer, 2013, 53, 93-98.	0.1	0
144	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 2149-2157.	4.1	81

#	Article	IF	Citations
145	Association between a Genome-Wide Association Study-Identified Locus and the Risk of Lung Cancer in Japanese Population. Journal of Thoracic Oncology, 2012, 7, 790-798.	1.1	37
146	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. Journal of Thoracic Oncology, 2012, 7, 1078-1085.	1.1	34
147	Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation. Journal of Thoracic Oncology, 2012, 7, 1640-1644.	1.1	107
148	EGFR Gene Mutations: Is it Prognostic or Predictive in Surgically Resected Lung Cancer?. Journal of Thoracic Oncology, 2012, 7, 1739-1741.	1.1	4
149	Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211.	2.0	35
150	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer, 2012, 77, 319-325.	2.0	102
151	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics, 2012, 44, 1330-1335.	21.4	286
152	Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Nonâ€“Small-Cell Lung Cancers. Clinical Lung Cancer, 2012, 13, 488-493.	2.6	12
153	Conversion from the â€œoncogene addictionâ€•to â€œdrug addictionâ€•by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 2012, 76, 292-299.	2.0	56
154	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutationâ€”diversity, ductility, and destiny. Cancer and Metastasis Reviews, 2012, 31, 807-814.	5.9	132
155	A Screening Method for the ALK Fusion Gene in NSCLC. Frontiers in Oncology, 2012, 2, 24.	2.8	71
156	A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer, 2012, 118, 6126-6135.	4.1	111
157	Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. International Journal of Clinical Oncology, 2012, 17, 218-224.	2.2	26
158	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521.	1.6	71
159	Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).. Journal of Clinical Oncology, 2012, 30, TPS7110-TPS7110.	1.6	7
160	Comparisons of the New TNM Staging System for Lung Cancer (UICC-7) and Revisions of the General Rules for the Clinical and Pathological Classification of Lung Cancer of the Japan Lung Cancer Society. Japanese Journal of Lung Cancer, 2012, 52, 80-84.	0.1	1
161	Lung Adenocarcinoma Coexistent with Pulmonary Non-tuberculous Mycobacteriosis. Japanese Journal of Lung Cancer, 2012, 52, 238-241.	0.1	1
162	Abstract IA5: Genetic and genomic difference in lung cancer based on ethnicity. Clinical Cancer Research, 2012, 18, IA5-IA5.	7.0	0

#	Article	IF	Citations
163	Oncogenic driver mutations. , 2012, , 45-58.		0
164	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. , 2012, 3, 438-43.		4
165	Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15.	2.0	78
166	Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer, 2011, 74, 139-144.	2.0	132
167	Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. Lancet Oncology, The, 2011, 12, 710-711.	10.7	34
168	Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1152-1161.	1.1	233
169	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. International Journal of Clinical Oncology, 2011, 16, 294-305.	2.2	23
170	Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	0.9	60
171	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Annals of Pharmacotherapy, 2011, 45, 263-275.	1.9	0
172	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology, 2011, 6, 2011-2017.	1.1	196
173	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	1.1	4,127
174	A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201). Journal of Thoracic Oncology, 2011, 6, 751-756.	1.1	505
175	Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2972-2977.	1.6	218
176	Analysis of ERBB4 Mutations and Expression in Japanese Patients with Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1859-1861.	1.1	9
177	Small peripheral lung adenocarcinoma: Clinicopathological features and surgical treatment. Surgery Today, 2010, 40, 191-198.	1.5	19
178	Validation of a Nomogram for Predicting Overall Survival After Resection of Pulmonary Metastases from Colorectal Cancer at a Single Center. World Journal of Surgery, 2010, 34, 2973-2978.	1.6	16
179	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Journal of Cancer Research and Clinical Oncology, 2010, 136, 527-535.	2.5	15
180	Lymph node metastasis of an esophageal cancer behind the thoracic descending aorta. Esophagus, 2010, 7, 111-114.	1.9	5

#	Article	IF	Citations
181	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	5.9	191
182	Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable nonâ€“small cell lung cancer: A large-scale retrospective cohort study applying a propensity score. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1001-1006.	0.8	107
183	Salvage surgery for advanced nonâ€“small cell lung cancer after response to gefitinib. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, e69-e71.	0.8	52
184	Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study. Surgical Oncology, 2010, 19, e144-e149.	1.6	11
185	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS Journal, 2010, 277, 301-308.	4.7	456
186	Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341.	0.1	0
187	Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer. Clinical Cancer Research, 2010, 16, 3349-3355.	7.0	108
188	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. Therapeutic Advances in Medical Oncology, 2010, 2, 301-307.	3.2	33
189	Molecular Diagnosis of Activating EGFR Mutations in Nonâ€“Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis. Clinical Cancer Research, 2010, 16, 3163-3170.	7.0	108
190	Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stressâ€“Response Pathways. Cancer Research, 2010, 70, 9949-9958.	0.9	23
191	Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clinical Cancer Research, 2010, 16, 5489-5498.	7.0	200
192	Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 101-106.	1.3	73
193	Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. Carcinogenesis, 2010, 31, 660-665.	2.8	38
194	Lung Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i7-i12.	1.3	17
195	Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons. Journal of Molecular Diagnostics, 2010, 12, 644-652.	2.8	14
196	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	10.7	3,794
197	EGFR mutations in non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2010, 11, 413.	10.7	1
198	EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine, 2010, 363, 1734-1739.	27.0	1,124

#	Article	IF	Citations
199	Adjuvant Chemotherapy in Patients with Completely Resected Lung Cancer: Investigation of the Current Situation After Publication of the Second Edition of Clinical Practice Guidelines for Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 280-286.	0.1	1
200	Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers. Journal of Thoracic Oncology, 2009, 4, 5-11.	1.1	283
201	EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?. Journal of Thoracic Oncology, 2009, 4, 1-4.	1.1	167
202	Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses. Cancer Research, 2009, 69, 4027-4035.	0.9	32
203	Relapse-Related Molecular Signature in Lung Adenocarcinomas Identifies Patients With Dismal Prognosis. Journal of Clinical Oncology, 2009, 27, 2793-2799.	1.6	194
204	Comparison of methods for placing and managing a silastic drain after pulmonary resection. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 645-648.	1.1	3
205	Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Nonâ€“Small Cell Lung Cancer with EGFR Mutations. Clinical Cancer Research, 2009, 15, 4493-4498.	7.0	182
206	Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with nonâ€smallâ€cell lung cancer for gefitinib treatment. Cancer Science, 2009, 100, 1931-1934.	3.9	15
207	Fluid Drainage and Air Evacuation Characteristics of Blake and Conventional Drains Used After Pulmonary Resection. Annals of Thoracic Surgery, 2009, 87, 1539-1545.	1.3	27
208	Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer, 2009, 63, 241-246.	2.0	17
209	Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer, 2009, 63, 315-321.	2.0	107
210	Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. Lung Cancer, 2009, 64, 41-44.	2.0	22
211	Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis. Lung Cancer, 2009, 66, 309-313.	2.0	30
212	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. Journal of Human Genetics, 2009, 54, 739-745.	2.3	50
213	Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 22-29.	1.1	222
214	Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib. Journal of Thoracic Oncology, 2009, 4, 1415-1419.	1.1	151
215	EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. Journal of Thoracic Oncology, 2009, 4, 318-325.	1.1	52
216	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.1	0

#	Article	IF	Citations
217	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General Thoracic and Cardiovascular Surgery, 2008, 56, 97-103.	0.9	38
218	Predictors of Survival in Patients With Bone Metastasis of Lung Cancer. Clinical Orthopaedics and Related Research, 2008, 466, 729-736.	1.5	227
219	Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. Journal of Surgical Oncology, 2008, 98, 510-514.	1.7	14
220	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinibâ€treated patients with lung adenocarcinoma. Cancer Science, 2008, 99, 303-308.	3.9	37
221	Soy consumption reduces the risk of nonâ€smallâ€cell lung cancers with epidermal growth factor receptor mutations among Japanese. Cancer Science, 2008, 99, 1202-1208.	3.9	28
222	Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected nonâ€“small cell lung cancers. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1343-1348.	0.8	23
223	Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural InvasionâŽâŽThe main results from this paper were previously published in the Japanese Journal of Lung Cancer, in Japanese [16].. Annals of Thoracic Surgery, 2008, 86, 1084-1090.	1.3	22
224	Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures. Annals of Thoracic Surgery, 2008, 86, 1076-1083.	1.3	16
225	Phase II Trial of Preoperative Chemoradiotherapy Followed by Surgical Resection in Patients With Superior Sulcus Nonâ€“Small-Cell Lung Cancers: Report of Japan Clinical Oncology Group Trial 9806. Journal of Clinical Oncology, 2008, 26, 644-649.	1.6	182
226	Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 6092-6096.	7.0	159
227	Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. Cancer Research, 2008, 68, 2106-2111.	0.9	134
228	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptorâ€“Activating Mutations. Cancer Research, 2008, 68, 9479-9487.	0.9	574
229	Increased Prevalence ofEGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms. Clinical Cancer Research, 2008, 14, 4079-4084.	7.0	71
230	The Significance of Changes in Serum CEA Level as a Surrogate Marker for Evaluating Tumor Response to Chemotherapy in Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2008, 48, 26-32.	0.1	0
231	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
232	A 25-Signal Proteomic Signature and Outcome for Patients With Resected Nonâ€“Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 858-867.	6.3	73
233	Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. Cancer Research, 2007, 67, 6007-6011.	0.9	200
234	Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a caseâ€“control study. Carcinogenesis, 2007, 28, 1718-1725.	2.8	68

#	Article	IF	Citations
235	Controversy about Small Peripheral Lung Adenocarcinomas: How Should We Manage Them?. Journal of Thoracic Oncology, 2007, 2, 546-552.	1.1	15
236	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology, 2007, 2, 321-324.	1.1	5
237	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	1.1	71
238	Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancerâ€"From studies of 604 surgical cases. Lung Cancer, 2007, 57, 311-316.	2.0	16
239	M03-01: Molecular predictors of EGFR-TKIs. Journal of Thoracic Oncology, 2007, 2, S156.	1.1	2
240	Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene, 2007, 26, 4600-4608.	5.9	43
241	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Science, 2007, 98, 96-101.	3.9	86
242	Genomic profiling of malignant pleural mesothelioma with arrayâ€based comparative genomic hybridization shows frequent nonâ€random chromosomal alteration regions including JUN amplification on 1p32. Cancer Science, 2007, 98, 438-446.	3.9	86
243	LKB1 gene mutations in Japanese lung cancer patients. Cancer Science, 2007, 98, 1747-1751.	3.9	51
244	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	3.9	554
245	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	1.3	72
246	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 316, 1039-1043.	12.6	4,187
247	Neuroendocrine tumor metastasis to the thyroid gland. International Journal of Clinical Oncology, 2007, 12, 63-67.	2.2	18
248	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	1.1	134
249	New TNM Classification for Non-small Cell Lung Cancer by Evaluating T Factor Based on Tumor Size and Visceral Pleural Invasion. Japanese Journal of Lung Cancer, 2007, 47, 1-8.	0.1	1
250	Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2007, 47, 327-332.	0.1	0
251	Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, 22-8.	1.1	69
252	A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer. Journal of Molecular Diagnostics, 2006, 8, 335-341.	2.8	178

#	Article	IF	Citations
253	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 120-125.	1.1	58
254	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 629-634.	1.1	28
255	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 629-634.	1.1	68
256	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 120-125.	1.1	94
257	Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology, 2006, 11, 190-198.	2.2	194
258	Mutations of epidermal growth factor receptor andK-rasgenes in adenosquamous carcinoma of the lung. International Journal of Cancer, 2006, 118, 1588-1590.	5.1	66
259	Expression Profileâ€“Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. Journal of Clinical Oncology, 2006, 24, 1679-1688.	1.6	296
260	Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Nonâ€“Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clinical Cancer Research, 2006, 12, 5764-5769.	7.0	577
261	EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro-Oncology, 2006, 8, 137-144.	1.2	80
262	Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2006, 46, 237-240.	0.1	0
263	Relationship Between Prognosis and Nodal Micrometastasis in Patients With Non-Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2006, 46, 23-26.	0.1	0
264	PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. Journal of Thoracic Oncology, 2006, 1, 629-34.	1.1	53
265	EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma. American Journal of Surgical Pathology, 2005, 29, 633-639.	3.7	229
266	Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Science, 2005, 96, 111-115.	3.9	573
267	Throwing new light on lung cancer pathogenesis: Updates on three recent topics. Cancer Science, 2005, 96, 63-68.	3.9	19
268	EGFRMutation and Response of Lung Cancer to Gefitinib. New England Journal of Medicine, 2005, 352, 2136-2136.	27.0	118
269	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Nonâ€“Small-Cell Lung Cancer With Postoperative Recurrence. Journal of Clinical Oncology, 2005, 23, 2513-2520.	1.6	922
270	Mass Screening and Molecular Diagnosis for Lung Cancer. Japanese Journal of Lung Cancer, 2005, 45, 157-165.	0.1	0

#	Article	IF	Citations
271	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Personalized Medicine, 2004, 1, 27-34.	1.5	5
272	Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction. Journal of Clinical Oncology, 2004, 22, 811-819.	1.6	148
273	Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis, 2004, 25, 1395-1401.	2.8	126
274	Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene, 2004, 23, 4041-4049.	5.9	52
275	Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene, 2004, 23, 5360-5370.	5.9	140
276	CK20 expression, CDX2 expression,K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. Journal of Pathology, 2004, 203, 645-652.	4.5	88
277	Interferon-? differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. International Journal of Cancer, 2004, 110, 403-412.	5.1	26
278	Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International Journal of Cancer, 2004, 112, 26-32.	5.1	203
279	Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. Cancer Research, 2004, 64, 3753-3756.	0.9	2,287
280	Identification of MGB1 as a Marker in the Differential Diagnosis of Lung Tumors in Patients with a History of Breast Cancer by Analysis of Publicly Available SAGE Data. Journal of Molecular Diagnostics, 2004, 6, 90-95.	2.8	15
281	Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer. Cancer Research, 2004, 64, 8919-8923.	0.9	1,168
282	RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. International Journal of Cancer, 2003, 106, 45-51.	5.1	65
283	Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer, 2003, 42, 23-33.	2.0	123
284	The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (â€˜Iressaâ€™11Iressaâ€™ is a trademark of the AstraZeneca group of companies.) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer, 2003, 42, 35-41.	2.0	64
285	Analysis of Î²-tubulin gene alteration in human lung cancer cell lines. Cancer Letters, 2003, 201, 211-216.	7.2	15
286	TTF-1 Expression in Pulmonary Adenocarcinomas. American Journal of Surgical Pathology, 2002, 26, 767-773.	3.7	352
287	A Limited Association of OGG1 Ser326Cys Polymorphism for Adenocarcinoma of the Lung.. Journal of Epidemiology, 2002, 12, 258-265.	2.4	69
288	A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: The incidence of carcinomatous pleuritis after surgical intervention. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 695-699.	0.8	47

#	Article	IF	Citations
289	Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene, 2002, 21, 2328-2333.	5.9	119
290	Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene, 2002, 21, 2822-2828.	5.9	48
291	Decreased expression of 14-3-3Ïƒ in neuroendocrine tumors is independent of origin and malignant potential. Oncogene, 2002, 21, 8310-8319.	5.9	30
292	Completely resected stage IIIA nonâ€“small cell lung cancer: The significance of primary tumor location and N2 station. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 803-808.	0.8	109
293	Persistent Increase in Chromosome Instability in Lung Cancer. American Journal of Pathology, 2001, 159, 1345-1352.	3.8	45
294	Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer, 2001, 34, 29-36.	2.0	82
295	Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery, 2001, 49, 545-551.	0.4	16
296	Topographical Distributions of Allelic Loss in Individual Non-Small-Cell Lung Cancers. American Journal of Pathology, 2000, 157, 985-993.	3.8	25
297	Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Annals of Thoracic Surgery, 2000, 70, 401-405.	1.3	36
298	MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Annals of Thoracic Surgery, 1999, 67, 810-814.	1.3	36
299	Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer, 1998, 20, 117-125.	2.0	30
300	Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Annals of Thoracic Surgery, 1997, 64, 363-367.	1.3	90
301	Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 535-543.	0.8	103
302	Mutations of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 354-360.	0.8	55
303	Combined Carboplatin and Cisplatin Therapy in Patients with Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 31-35.	1.3	0
304	Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis. Journal of Surgical Oncology, 1996, 61, 218-222.	1.7	60
305	Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. , 1996, 63, 159-165.		26
306	Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis. Journal of Surgical Oncology, 1996, 61, 218-222.	1.7	2

#	Article	IF	Citations
307	Serum Level and Tissue Expression of c-erbB-2 Protein in Lung Adenocarcinoma. Chest, 1995, 108, 157-162.	0.8	38
308	Successful management of tracheo-innominate artery fistula using interposition of a thymus pedicle flap. Journal of Laryngology and Otology, 1995, 109, 161-162.	0.8	12
309	Characteristics of non-small cell lung cancer 3 cm or less in diameter. Journal of Surgical Oncology, 1995, 59, 251-254.	1.7	7
310	Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. International Archives of Occupational and Environmental Health, 1995, 67, 253-256.	2.3	67
311	CT and MRI manifestations of primary pulmonary plasmacytoma. Clinical Imaging, 1995, 19, 17-19.	1.5	11
312	Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 1995, 121, 291-296.	2.5	25
313	The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. European Journal of Surgical Oncology, 1995, 21, 398-402.	1.0	0
314	p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. Chest, 1994, 106, 377S-381S.	0.8	43
315	Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines. Human Genetics, 1994, 93, 27-31.	3.8	6
316	Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biological Trace Element Research, 1994, 42, 115-127.	3.5	47
317	Surgical treatment of lung cancer in the octogenarian. Annals of Thoracic Surgery, 1994, 57, 188-192.	1.3	105
318	Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer, 1994, 10, S73-S81.	2.0	3
319	Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. Annals of Thoracic Surgery, 1993, 55, 511-513.	1.3	5
320	Aspergilloma Within Cavitating Pulmonary Carcinoma: Case Report. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1993, 27, 57-60.	0.2	10
321	Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 1993, 85, 2018-2023.	6.3	196
322	Papillary Carcinoma in A Huge Intrathoracic Goiter with Tracheal Stenosis and Invasion. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1993, 27, 165-168.	0.2	2
323	Mediastinal tumors associated with von Recklinghausen's disease.. The Journal of the Japanese Association for Chest Surgery, 1992, 6, 780-785.	0.0	0
324	Cavernous lymphangioma extending to the posterior mediastinum and the retroperitoneum; a case report.. The Journal of the Japanese Association for Chest Surgery, 1992, 6, 706-711.	0.0	0

#	Article	IF	Citations
325	Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. European Journal of Cancer & Clinical Oncology, 1991, 27, 1372-1375.	0.7	161
326	Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. Biochemical and Biophysical Research Communications, 1991, 181, 1539-1547.	2.1	25
327	DNA polymerase-Î± as a putative early relapse marker in non-small cell lung cancer. An immunohistochemical study. Cancer, 1991, 68, 925-929.	4.1	11
328	Large Cell Carcinoma of the Lung: Prognostic Implications of Histopathologic and Immunohistochemical Subtyping. American Journal of Clinical Pathology, 1990, 93, 176-182.	0.7	26
329	Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. Cellular Immunology, 1989, 122, 578-584.	3.0	13
330	A clinicopathological study of gastric cancer with special reference to age of the patients: An analysis of 1,630 cases. World Journal of Surgery, 1989, 13, 225-230.	1.6	56
331	Longer survival after resection of non-small cell lung cancer in Japanese women. Annals of Thoracic Surgery, 1989, 48, 639-642.	1.3	51
332	Inflammatory pseudotumor of the lung in adults: Radiographic and clinicopathological analysis. Annals of Thoracic Surgery, 1989, 48, 90-95.	1.3	75
333	Abortive transformation of temperature-sensitive mutants of rat 3Y1 cells by simian virus 40: Effect of cellular arrest states on entry into S phase and cellular proliferation. Journal of Cellular Physiology, 1985, 123, 353-360.	4.1	16
334	EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence. Journal of Cancer Research Updates, 0, , .	0.3	0